

Last Resort Clinic Bioinformatics Platform




LaRC BP

Medical Team:

William Gormley, MD, MPH (Brigham & Womens Hospital)

Joan LaRovere, MD, MSc (Children's Hospital)

Sergei Sobolevsky, MD (Maomonides Hospital)



Last Resort Clinic Bioinformatics Platform

LaRC BP



Pharma/Biotech Team:

Leah Isakov (Pfizer)

Lovisa Afzelius (Pfizer)

Jay Dong (Beckton Dickinson)

Zhengjie Sophie Sun (Merck. EMD Serono)



Last Resort Clinic Bioinformatics Platform

LaRC BP

Financial Team:

Xiao Le (MIT Sloan)

Vahid Montazerhodjat (MIT Sloan)


Sergio Humeda Gomez (Cineapolis)

Mission Statement

Develop a multi-institutional **bioinformatics platform** for acceleration of discovery of oncology solutions via construction of a comprehensive library of tissue data accessible to pharmaceutical industry, clinical and scientific partners

The Players

- Segment 1: Oncology patients
- Segment 2: Clinical Institutions & Oncologists
- Segment 3: Pharmaceutical corporations
- Segment 4: Molecular Based Scientific Institutions
- Segment 5: Patient Advocacy Groups



Basic Business Model

1. Collection of tissue specimens

- normal tissue

- tumor tissue

1. Analysis of tissue

- DNA/RNA sequencing, metabolomics, proteinomics, etc

2. Developing data libraries

3. Access to data by subscribers (i.e. pharma, biotech)

4. Development and maintenance of the platform by existing data management platforms (i.e. Google)

Financial Model

- Non-profit organization
- Multiple partnerships
 - Clinical Academic Partners
 - Pharmaceutical, Bio-tech and Diagnostic Corporations
 - Bio-informatics Data generation institutions
 - Patient Advocacy group
- Shared intellectual property

Financial Model: Phases Development

Phase I – Establishment Phase

Early establishment of system and data platform

Phase II – Discovery phase

Revenue and Cash flow generation from ongoing discovery.

Sources of Revenue: Establishment Phase

- Pharmaceutical Industry
 - Fees for participation
 - Recuperating financial commitment through the following mechanisms
 - Acceleration of innovative molecules
 - New indication for existing approved medications
 - Identification of non effective molecules early in development

Sources of Revenue: Establishment Phase

- Philanthropy
- Government via NIH
- Insurance carriers in the form of partnership grants
- Department of defense

Sources of Revenue: Discovery Phase

- Patents and licensing of new discoveries made within the organization
- “Orphan Disease”
Reformulating “off patent” drugs as “Orphan Drugs”
- Pharmaceutical and Bio-tech
Fees and royalties on jointly discovered molecules

